Having trouble accessing articles? Reset your cache.

FDA names, shames ‘anticompetitive’ drug companies

FDA Commissioner Scott Gottlieb Thursday made public a list of 41 branded drug companies that generics manufacturers have accused of blocking access to drug samples to thwart development of competitive generic drugs.

The list includes complaints about branded drugmakers improperly using REMS requirements to restrict access to samples of branded drugs that are necessary to conduct

Read the full 565 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE